WO1998006753A3 - P53 mutant - Google Patents

P53 mutant Download PDF

Info

Publication number
WO1998006753A3
WO1998006753A3 PCT/IB1997/001275 IB9701275W WO9806753A3 WO 1998006753 A3 WO1998006753 A3 WO 1998006753A3 IB 9701275 W IB9701275 W IB 9701275W WO 9806753 A3 WO9806753 A3 WO 9806753A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutants
domain
relates
mutant
subjects
Prior art date
Application number
PCT/IB1997/001275
Other languages
French (fr)
Other versions
WO1998006753A2 (en
Inventor
Arnold Jay Levine
Kristen Kay Walker
Original Assignee
Univ Princeton
Arnold Jay Levine
Kristen Kay Walker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton, Arnold Jay Levine, Kristen Kay Walker filed Critical Univ Princeton
Priority to AU43946/97A priority Critical patent/AU4394697A/en
Publication of WO1998006753A2 publication Critical patent/WO1998006753A2/en
Publication of WO1998006753A3 publication Critical patent/WO1998006753A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to p53 mutants which have lost the ability interact with other proteins or compounds or to bind a SH-3 domain, as well as nucleic acids encoding these mutants, suitable expression systems and uses of such subjects matters, e.g. for the development of pharmaceutical agents. The invention further relates to peptides derivable from the proline rich domain of p53.
PCT/IB1997/001275 1996-08-13 1997-08-05 P53 mutant WO1998006753A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43946/97A AU4394697A (en) 1996-08-13 1997-08-05 P53 mutant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68974896A 1996-08-13 1996-08-13
US08/689,748 1996-08-13

Publications (2)

Publication Number Publication Date
WO1998006753A2 WO1998006753A2 (en) 1998-02-19
WO1998006753A3 true WO1998006753A3 (en) 1998-04-23

Family

ID=24769765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1997/001275 WO1998006753A2 (en) 1996-08-13 1997-08-05 P53 mutant

Country Status (2)

Country Link
AU (1) AU4394697A (en)
WO (1) WO1998006753A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801695D0 (en) * 1998-05-14 1998-05-14 Karolinska Innovations Ab Inhibition of p53 function by a p53-derived peptide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008241A1 (en) * 1992-09-30 1994-04-14 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Process for detecting p53-specific antibodies
WO1995009916A1 (en) * 1993-10-04 1995-04-13 Rhone-Poulenc Rorer S.A. Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
WO1995014777A1 (en) * 1993-11-22 1995-06-01 Onyx Pharmaceuticals p53-BINDING POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME
WO1995019367A1 (en) * 1994-01-14 1995-07-20 La Jolla Cancer Research Foundation Screening assays for identifying agents that affect p53-dependent expression
WO1996016989A1 (en) * 1994-11-28 1996-06-06 The Wistar Institute Of Anatomy And Biology p53 PROTEINS WITH ALTERED TETRAMERIZATION DOMAINS
WO1996025434A1 (en) * 1995-02-16 1996-08-22 The Wistar Institute PEPTIDES AND PEPTIDOMIMETICS WITH STRUCTURAL SIMILARITY TO HUMAN p53 THAT ACTIVATE p53 FUNCTION

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008241A1 (en) * 1992-09-30 1994-04-14 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Process for detecting p53-specific antibodies
WO1995009916A1 (en) * 1993-10-04 1995-04-13 Rhone-Poulenc Rorer S.A. Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
WO1995014777A1 (en) * 1993-11-22 1995-06-01 Onyx Pharmaceuticals p53-BINDING POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME
WO1995019367A1 (en) * 1994-01-14 1995-07-20 La Jolla Cancer Research Foundation Screening assays for identifying agents that affect p53-dependent expression
WO1996016989A1 (en) * 1994-11-28 1996-06-06 The Wistar Institute Of Anatomy And Biology p53 PROTEINS WITH ALTERED TETRAMERIZATION DOMAINS
WO1996025434A1 (en) * 1995-02-16 1996-08-22 The Wistar Institute PEPTIDES AND PEPTIDOMIMETICS WITH STRUCTURAL SIMILARITY TO HUMAN p53 THAT ACTIVATE p53 FUNCTION

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRANDT-RAUF P.W. ET AL.: "Conformational effects of environmentally induced, cancer-related mutations in the p53 protein", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, no. 20, September 1994 (1994-09-01), pages 9262 - 9266, XP002055273 *
LIN J. ET AL.: "Several hydrophobic amino acids in the p53 amino terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55.kD protein", GENES & DEVELOPMENT, vol. 8, 1994, pages 1235 - 1246, XP000619245 *
WALKER K.K. ET LEVINE A.J.: "Identification of a novel p53 functional domain that is necessary for efficient growth suppression", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, December 1996 (1996-12-01), pages 15335 - 15340, XP002055272 *
YU H. ET AL.: "Structural Basis for the Binding of Proline-Rich Peptides to SH3 Domains", CELL, vol. 76, 1994, pages 933 - 945, XP000578240 *

Also Published As

Publication number Publication date
AU4394697A (en) 1998-03-06
WO1998006753A2 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
WO2000023564A3 (en) Protein design automation for protein libraries
AU642403B2 (en) Method for the use and synthesis of peptides
WO2000001815A3 (en) Neurotrophic factors
AU1843395A (en) Antibody purification
EP0832973A3 (en) GTP-binding protein
CA2266319A1 (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
WO2002038592A3 (en) Peptides, the production and use thereof for binding immunoglobulins
EP0913476A3 (en) Ornithine carbamoyl transferase sequence and uses thereof
EP0825260A3 (en) Arginase II
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
AU4367196A (en) Novel protein domain which binds tyrosine phosphorylated proteins
AU9550198A (en) Jmy, a co-activator for p300/cbp, nucleic acid encoding jmy and uses thereof
WO1997012039A3 (en) Sh2-containing inositol-phosphatase
AU2001287040A1 (en) Methods of designing and producing novel compounds having improved binding affinity for cd154 or other trimeric proteins
EP0931834A3 (en) Echinocandin binding domain of 1,3-Beta-glucan synthase
AU3711597A (en) A novel galanin receptor
WO1999004266A3 (en) Interactions of atm, atr or dna-pk with p53
AUPP627498A0 (en) Novel peptides - i
WO1998006753A3 (en) P53 mutant
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
AU2001292118A1 (en) Dye-labelled peptide and its diagnostic use
WO1999028465A3 (en) Pias molecules that recognize and bind stat proteins and uses thereof
DE69610174D1 (en) Bridge part, especially for overcoming trenches by vehicles
CA2199843A1 (en) Novel PKA-Binding Proteins and Uses Thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998509549

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA